Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal

Detalhes bibliográficos
Autor(a) principal: Marques, Joana Isabel
Data de Publicação: 2013
Outros Autores: Ribeiro Vaz, Inês, Santos, Cristina, Polónia, Jorge
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102
Resumo: Introduction: Healthcare professionals were a priority group for Pandemrix® vaccination. Surveying this particularly committed group for vaccination related side effects could help to get valuable information about vaccine safety profile. Our aim was to identify the adverse events following immunization with Pandemrix® among healthcare professionals. Material and Methods: A questionnaire for active post-authorization monitoring of adverse events following immunization with the influenza vaccine A (H1N1) was designed and distributed to the vaccinated healthcare professionals working at 3 elected hospital centres in the Northern region, in the period from 26 October 2009 to 31 January 2010. Results: From the 2358 vaccinated healthcare professionals that accepted to participate in this study, 864 (37%) returned back the fulfill questionnaire on time. Among these, 634 (73%) of healthcare professionals experienced at least one adverse event following immunization, but only 8% experienced an unexpected one. The adverse events most frequently reported were expected and very common: local reactions at the injection site (57%), myalgia (31%), fatigue (including asthenia) (24%) and headache (19%). No cases of major episodes, such as death or life-threatening events were reported. Female gender and existence of underlying conditions were independent risk factors to develop at least one adverse event following immunization to the pandemic vaccine. Conclusions: Our work suggests an acceptable safety profile of this pandemic flu vaccine among healthcare professionals. Both frequency and severity of the observed adverse event following immunization do not seem to be higher than expected.
id RCAP_03b375708b057dac212b3d7ef78be227
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/4102
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in PortugalEventos Adversos com a Vacina Pandemrix® Contra o Vírus Influenza A(H1N1) em Profissionais de Saúde em PortugalIntroduction: Healthcare professionals were a priority group for Pandemrix® vaccination. Surveying this particularly committed group for vaccination related side effects could help to get valuable information about vaccine safety profile. Our aim was to identify the adverse events following immunization with Pandemrix® among healthcare professionals. Material and Methods: A questionnaire for active post-authorization monitoring of adverse events following immunization with the influenza vaccine A (H1N1) was designed and distributed to the vaccinated healthcare professionals working at 3 elected hospital centres in the Northern region, in the period from 26 October 2009 to 31 January 2010. Results: From the 2358 vaccinated healthcare professionals that accepted to participate in this study, 864 (37%) returned back the fulfill questionnaire on time. Among these, 634 (73%) of healthcare professionals experienced at least one adverse event following immunization, but only 8% experienced an unexpected one. The adverse events most frequently reported were expected and very common: local reactions at the injection site (57%), myalgia (31%), fatigue (including asthenia) (24%) and headache (19%). No cases of major episodes, such as death or life-threatening events were reported. Female gender and existence of underlying conditions were independent risk factors to develop at least one adverse event following immunization to the pandemic vaccine. Conclusions: Our work suggests an acceptable safety profile of this pandemic flu vaccine among healthcare professionals. Both frequency and severity of the observed adverse event following immunization do not seem to be higher than expected.Introdução: Os profissionais de saúde foram um grupo prioritário para vacinação contra a pandemia da Gripe A (H1N1), Pandemrix®. Assim, monitorizar os eventos adversos relacionados com esta vacina neste grupo específico poderá originar informação valiosa relacionada com o perfil de segurança da vacina. O nosso objetivo foi identificar os eventos adversos após imunização com a vacina Pandemrix® em profissionais de saúde. Material e Métodos: Foi desenhado um questionário de monitorização dos eventos adversos ocorridos com a vacina Pandemrix®. O questionário foi distribuído aos profissionais de saúde a trabalhar em três centros hospitalares da região norte do País, vacinados no período de 26 de Outubro de 2009 a 31 de janeiro de 2009. Resultados: Dos 2358 profissionais de saúde que aceitaram participar no estudo, 864 (37%) devolveram o questionário preenchido. Destes, 73% experienciaram pelo menos um evento adverso após imunização, mas só 8% experienciaram um evento inesperado. Os eventos adversos mais frequentemente reportados foram os esperados e muito comuns: reações locais no local de administração (57%), mialgia (31%), fadiga (incluindo astenia) (24%) e dor de cabeça (19%). Não foram reportados casos de eventos de maior gravidade para a saúde, tais como morte ou risco de vida. O género feminino e a existência de doença de base foram fatores de risco independentes para o desenvolvimento de pelo menos um evento adverso após imunização com a Pandemrix®. Conclusões: O nosso trabalho sugere um perfil de segurança aceitável da vacina pandémica Pandermix® em profissionais de saúde. Tanto a frequência como a severidade dos eventos adversos não se verificaram superiores ao esperado.Ordem dos Médicos2013-05-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102oai:ojs.www.actamedicaportuguesa.com:article/4102Acta Médica Portuguesa; Vol. 26 No. 2 (2013): March-April; 107-112Acta Médica Portuguesa; Vol. 26 N.º 2 (2013): Março-Abril; 107-1121646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102/3234Marques, Joana IsabelRibeiro Vaz, InêsSantos, CristinaPolónia, Jorgeinfo:eu-repo/semantics/openAccess2022-12-20T11:03:15Zoai:ojs.www.actamedicaportuguesa.com:article/4102Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:18:41.697261Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
Eventos Adversos com a Vacina Pandemrix® Contra o Vírus Influenza A(H1N1) em Profissionais de Saúde em Portugal
title Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
spellingShingle Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
Marques, Joana Isabel
title_short Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
title_full Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
title_fullStr Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
title_full_unstemmed Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
title_sort Adverse Events with the Influenza A(H1N1) Vaccine Pandemrix® at Healthcare Professionals in Portugal
author Marques, Joana Isabel
author_facet Marques, Joana Isabel
Ribeiro Vaz, Inês
Santos, Cristina
Polónia, Jorge
author_role author
author2 Ribeiro Vaz, Inês
Santos, Cristina
Polónia, Jorge
author2_role author
author
author
dc.contributor.author.fl_str_mv Marques, Joana Isabel
Ribeiro Vaz, Inês
Santos, Cristina
Polónia, Jorge
description Introduction: Healthcare professionals were a priority group for Pandemrix® vaccination. Surveying this particularly committed group for vaccination related side effects could help to get valuable information about vaccine safety profile. Our aim was to identify the adverse events following immunization with Pandemrix® among healthcare professionals. Material and Methods: A questionnaire for active post-authorization monitoring of adverse events following immunization with the influenza vaccine A (H1N1) was designed and distributed to the vaccinated healthcare professionals working at 3 elected hospital centres in the Northern region, in the period from 26 October 2009 to 31 January 2010. Results: From the 2358 vaccinated healthcare professionals that accepted to participate in this study, 864 (37%) returned back the fulfill questionnaire on time. Among these, 634 (73%) of healthcare professionals experienced at least one adverse event following immunization, but only 8% experienced an unexpected one. The adverse events most frequently reported were expected and very common: local reactions at the injection site (57%), myalgia (31%), fatigue (including asthenia) (24%) and headache (19%). No cases of major episodes, such as death or life-threatening events were reported. Female gender and existence of underlying conditions were independent risk factors to develop at least one adverse event following immunization to the pandemic vaccine. Conclusions: Our work suggests an acceptable safety profile of this pandemic flu vaccine among healthcare professionals. Both frequency and severity of the observed adverse event following immunization do not seem to be higher than expected.
publishDate 2013
dc.date.none.fl_str_mv 2013-05-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102
oai:ojs.www.actamedicaportuguesa.com:article/4102
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/4102
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/4102/3234
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 26 No. 2 (2013): March-April; 107-112
Acta Médica Portuguesa; Vol. 26 N.º 2 (2013): Março-Abril; 107-112
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130638432862208